医学硕士论文参考文献一
1.Siegel, R?，et al?，Cancer statistics, 2014. CA Cancer J Clin，2014. 64(1): p.9-29.
2.Fan, L.，et al., Breast cancer in China. Lancet Oncol, 2014. 15(7): p. e279-89
3.Chambers, A.F.，A.C. Groom，and LC. MacDonald, Dissemination and growthof cancer cells in metastatic sites. Nat Rev Cancer，2002. 2(8); p. 563-72.
4.Christofori, G.，New signals from the invasive front. Nature, 2006. 441(7092):p. 444-50.
5.Gupta, G.R and J. Massague，Cancer metastasis: building a framework. Cell,2006.127(4): p. 679-95.
6.Fidler，I.J.，The pathogenesis of cancer metastasis: the seed and soil’hypothesis revisited. Nat Rev Cancer, 2003. 3(6): p. 453-8.
7.Paget, S.，The distribution of secondary growths in cancer of the breast. 1889.Cancer Metastasis Rev，1989. 8(2): p. 98-101.
8.Edlund, M.，S.Y. Sung, and L.W. Chung, Modulation of prostate cancergrowth in bone microenvironments. J Cell Biochon, 2004. 91(4): p. 686-705.
9.Triozzi，RL.，C. Eng，and A.D. Singh，Targeted therapy for uveal melanoma.Cancer Treat Rev, 2008. 34(3): p. 247-58.
10.Hess, K.R.，et al，Metastatic patterns in adenocarcinoma. Cancer，2006.106(7): p. 1624-33.
11.Patanaphan, V.，O.M. Salazar, and R. Risco, Breast cancer: metastatic patternsand their prognosis. South Med J，1988. 81(9): p. 1109-12.
12.Yin, J.J?，et al., TGF-beta signaling blockade inhibits PTHrP secretion bybreast cancer cells and bone metastases development. J Clin Invest, 1999.103(2): p. 197-206.
13.Minn，AJ.，et al?，Distinct organ-specific metastatic potential of inpidualbreast cancer cells and primary tumors. J Clin Invest, 2005.115(1): p, 44-55.
14.Schmidt-Kittler, 0., et al” From latent disseminated cells to overt metastasis:genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U SA，2003.100(13): p. 7737-42.
15.Spratt, J.S?，Re: Dormancy of mammary carcinoma after mastectomy. J NatlCancer Inst, 2000. 92(13): p. 1101.
16.Feld，R.，L.V. Rubinstein，and T.H. Weisenberger, Sites of recurrence inresected stage I non-small-cel lung cancer: a guide for future studies. J ClinOncol, 1984. 2(12): p. 1352-8.
17.Hoffinan，RC., A.M. Mauer, and E.E. Yokes, Lung cancer. Lancet, 2000.355(9202): p. 479-85.
18.Minna，J.D.，J.M. Kurie, and T. Jacks, A big step in the study of small cell lungcancer. Cancer Cell, 2003. 4(3): p. 163-6.
19.Klein, C.A” The systemic progression of human cancer: a focus on theinpidual disseminated cancer cell—the unit of selection. Adv Cancer Res,2003.89: p. 35-67.
20.Kang, Y?，et al.，A multigenic program mediating breast cancer metastasis tobone. Cancer Cell，2003. 3(6): p. 537-49.
21.Mimdy, G.R., Metastasis to bone: causes, consequences and therapeuticopportunities. Nat Rev Cancer, 2002. 2(8): p. 584-93.
22.Lee, Y.T., Patterns of metastasis and natural courses of breast carcinoma.Cancer Metastasis Rev, 1985, 4(2): p. 153-72.
23.Johansson, J.E., et al., Natural history of early, localized prostate cancer.JAMA, 2004. 291(22): p. 2713-9.
24.Nieto，J.M.Grossbard，and P. Kozuch, Metastatic pancreatic cancer 2008:is the glass less empty? Oncologist, 2008.13(5): p. 562-76.
25.Fearon, E.R. and B. Vogelstein，A genetic model for colorectal tumorigenesis.Cell, 1990. 61(5): p. 759-67.
26.Vogelstein，B.，et al., Genetic alterations during colorectal-tumor development.N Engl J Med, 1988. 319(9): p. 525-32.
27.Samuels, Y” et al,，High frequency of mutations of the PIK3CA gene in humancancers. Science, 2004. 304(5670): p. 554.
28.Baker, SJ., et al., Chromosome 17 deletions and p53 gene mutations incolorectal carcinomas. Science, 1989.244(4901): p. 217-21.
29.Markowitz, S.，et al., Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science，1995. 268(5215): p.1336-8.
30.Jones，S.，et al.，Comparative lesion sequencing provides insights into tumorevolution. Proc Natl Acad Sci USA, 2008.105(11): p. 4283-8.
31.Paku, S., et al. Organ-specificity of the extravasation process: anultrastructural study. Clin Exp Metastasis，2000.18(6): p. 481-92.
32.Lalor，RF.，et al.，Human hepatic sinusoidal endothelial cells can bedistinguished by expression of phenotypic markers related to their specialisedfunctions in vivo. World J Gastroenterol, 2006.12(34): p. 5429-39.
33.Weis, S.，et al., Endothelial barrier disruption by VEGF-mediated Src activitypotentiates tumor cell extravasation and metastasis. J Cell Biol, 2004. 167(2):p. 223-9.
34.Gupta，G.R，et al.，Mediators of vascular remodelling co-opted for sequentialsteps in lung metastasis. Nature, 2007. 446(7137); p. 765-70.
35.Kamoub, A.E., et al., Mesenchymal stem cells within tumour stroma promotebreast cancer metastasis. Nature, 2007. 449(7162): p. 557-63.
36.Padua，D.，et al.，TGFbeta primes breast tumors for lung metastasis seedingthrough angiopoietin-like 4. Cell，2008.133(1); p. 66-77.
37.Weil, RJ., et al., Breast cancer metastasis to the central nervous system. Am JPathol, 2005.167(4): p. 913-20.
38.Kedrin，D.，et al., Cell motility and cytoskeletal regulation in invasion andmetastasis. J MMimiary Gland Biol Neoplasia, 2007.12(2-3): p. 143-52.
39.Weber, G.R, Molecular mechanisms of metastasis. Cancer Lett，2008. 270(2):p. 181-90.
40.Bandyopadhyay, S.，et al” Interaction of KAIl on tumor cells with DARC onvascular endothelium leads to metastasis suppression, Nat Med，2006. 12(8): p.933-8.
医学硕士论文参考文献二
[1]M.R. Prausnitz, S. Mitragotri, R. Langer, Current status and future potential of transdermaldrug delivery, Nature reviews. Drug discovery, 3 (2004) 115-124.
[2]M.A. Miller, E. Pisani, The cost of unsafe injections. Bulletin of the World HealthOrganization, 77 (1999) 808-811.
[3]H.A. Benson，Transdermal drug delivery: penetration enhancement techniques，Current drugdelivery, 2 (2005) 23-33.
[4]D. Lunter, R. Daniels, Confocal Raman microscopic investigation of the effectiveness ofpenetration enhancers for procaine delivery to the skin. Journal of biomedical optics, 19 (2014)126015.
[5]H. Kalluri, A.K, Banga, Transdermal delivery of proteins, AAPS PharmSciTech, 12 (2011)431-441.
[6]C.H. Purdon, C.G, Azzi, J. Zhang, E.W. Smith, H.L Maibach, Penetration enhancement oftransdermal delivery—current permutations and limitations. Critical reviews in therapeuticdrug carrier systems, 21 (2004) 97-132.
[7]X. Pang，X. Yang, G. Zhai, Polymer-drug conjugates: recent progress on administration routes,Expert opinion on drug delivery, 11 (2014) 1075-1086
[8]B.M. Mishriky, A.S. Habib，Nicotine for postoperative analgesia; a systematic review andmeta-analysis, Anesthesia and analgesia, 119 (2014) 268-275.
[9]H. Gupta, RJ. Babu，Transdermal delivery: product and patent update, Recent patents on drugdelivery & formulation, 7 (2013) 184-205.
[10]M. Sugino, H. Todo，K. Sugibayashi, [Skin permeation and transdermal delivery systems ofdrugs: history to overcome barrier function in the stratum comeum], Yakugaku zasshi :Journal of the Pharmaceutical Society of Japan, 129 (2009) 1453-1458.
[11]M.D. Ridge, V. Wright, Mechanical properties of skin: a bioengineering study of skinstructure, Journal of applied physiology, 21 (1966) 1602-1606.
[12]Peptide and protein transdermal drug delivery. Drug discovery today. Technologies, 9 (2012)e71-el74.
[13]H. Li, Y. Yu, S. Faraji Dana, B. Li, C.Y. Lee, L. Kang，Novel engineered systems for oral,mucosal and transdermal drug delivery, Journal of drug taigeting, 21 (2013) 611-629
[14]J.E. Riviere, M.G. Papich, Potential and problems of developing transdermal patches forveterinary applications，Advanced drug delivery reviews, 50 (2001) 175-203.
[15]M.R. Prausnitz, R. Langer, Transdermal drug delivery. Nature biotechnology, 26 (2008)991261-1268.
[16]M. El-Badry, G. Fetih, D. Fathalla, F. Shakeel, Transdermal delivery of meloxicam usingniosomal hydrogels: in vitro and pharmacodynamic evaluation, Pharmaceutical developmentand technology, (2014) 1-7.
[17]K.S. Paudel, M. Milewski, C.L. Swadley, N.K. Brogden, P. Ghosh, A.L. Stinchcomb，Challenges and opportunities in dermal/transdermal delivery, Therapeutic delivery, 1 (2010)109-131.
[18]B.J. Aungst, Absorption enhancers: applications and advances, The AAPS journal, 14 (2012)10-18.
[19]R.K. Subedi，S.Y. Oh, M.K. Chun, H.K. Choi, Recent advances in transdermal drug delivery,Arch Pharm Res, 33 339-351.
[20]S.J. Newton, Chemical penetration enhancers, International journal of pharmaceuticalcompounding, 17 (2013) 370-374.
[21]Y. Chen, M. Wang, L. Fang, Biomaterials as novel penetration enhancers for transdermal anddermal drug delivery systems, Drug delivery, 20 (2013) 199-209.
[22]E.J. Park, J. Werner, N.B. Smith, Ultrasound mediated transdermal insulin delivery in pigsusing a lightweight transducer, Pharmaceutical research, 24 (2007) 1396-1401.
[23]N.B. Smith, S. Lee, K.K. Shung, Ultrasound-mediated transdermal in vivo transport ofinsulin with low-profile cymbal arrays. Ultrasound in medicine & biology, 29 (2003)1205-1210.
[24]T. Gratieri, D. Kalaria, Y.N. Kalia, Non-invasive iontophoretic delivery of peptides andproteins across the skin, Expert opinion on drug delivery, 8 (2011) 645-663.
[25]H. Chen, H. Zhu, J. Zheng, D. Mou, J. Wan, J. Zhang, T. Shi, Y. Zhao, H. Xu, X. Yang,Iontophoresis-driven penetration of nanovesicles through microneedle-induced skinmicrochannels for enhancing transdermal delivery of insulin, Journal of controlled release :official journal of the Controlled Release Society, 139 (2009) 63-72.
[26]A.V. Badkar, A.M. Smith, J.A. Eppstein，A.K. Banga, Transdermal delivery of interferonalpha-2B using microporation and iontophoresis in hairless rats, Pharmaceutical research, 24(2007) 1389-1395.
[27]A. Pattani, P.F. McKay, M.J. Garland, R.M. Curran, K_ Migalska, C.M. Cassidy, R.K.Malcolm, R.J. Shattock, H.O. McCarthy, R.F. Donnelly, Microneedle mediated intradermaldelivery of adjuvanted recombinant HIV-1 CN54gpl40 effectively primes mucosal boostinoculations，Journal of controlled release ; official journal of the Controlled Release Society,162 (2012) 529-537.
[28]K. van der Maaden, W. Jiskoot, J. Bouwstra, Microneedle technologies for (trans)dermal drugand vaccine delivery, Journal of controlled release : official journal of the Controlled ReleaseSociety, 161 (2012) 645-655.
[29]Y.C. Kim, PJ. Ludovice，M.R. Pramnitz, Transdermal delivery enhanced by maininpore-forming peptide，Journal of controlled release : official journal of the ControlledRelease Society, 122 (2007) 375-383.
[30]J.B. Rothbard, S. Garlington, Q. Lin, T. Kirschbeig, E. Kreider, RL. McGrane, P.A. Wender,P.A. Khavari, Conjugation of arginitie oligomers to cyclosporin A facilitates topical deliveryand inhibition of inflammation. Nature medicine，6 (2000) 1253-1257.
[31]Y. Yang, R. Ou, S. Guan, X. Ye, B. Hu，Y. Zhang，S. Lu，Y. Zhou, Z. Yuan, J. Zhang, Q.G. Li,A novel drug delivery gel of terbinafine hydrochloride with high penetration for external use.Drug delivery, (2014).
[32]H. Chen, Y. Guan, Q. Zhong, Microemulsions Based on a Sunflower Lecithin-Tween 20Blend Have High Capacity for Dissolving Peppermint Oil and Stabilizing Coenzyme Q，Journal of agricultural and food chemistry, (2015)
[33]P.K, Ghosh，R.S. Murthy, Microemulsions: a potential drug delivery system, Current drugdelivery, 3 (2006) 167480.
[34]H.C. Vadlamudi, H. Narendran, T. Nagaswaram, G. Yaga, J, Thaimini, P.R. Yalavarthi,Microemulsions based transdermal drug delivery systems, Current drug discoverytechnologies, 11 (2014) 169-180.
[35]S. Duangjit, Y. Obata, H. Sano, Y. Onuki, P. Opanasopit, T. Ngawhirunpat, T. Miyoshi, S.Kato，K. Takayama, Comparative study of novel ultradeformable liposomes: menthosomes,transfersomes and liposomes for enhancing skin permeation of meloxicam, Biological &pharmaceutical bulletin, 37 (2014) 239-247.
[36]F. S. Guo，Y. Gan, X. Zhang, Preparation of redispersible liposomal dry powder using anultrasonic spray freeze-drying technique for transdermal delivery of human epithelial growthfactor. International journal of nanomedicine, 9 (2014) 1665-1676.
[37]F, Milletti, Cell-penetrating peptides; classes, origin, and current landscape, Drug discoverytoday, 17 (2012) 850-860.
[38]J.J. Turner, S. Jones, MM. Fabani, G. Ivanova, A.A. Arzumanov, MJ. Gait, RNA targetingwith peptide conjugates of oligonucleotides, siRNA and PNA，Blood cells, molecules &diseases, 38 (2007) 1-7.
[39]A.D. Frankel, C.O. Pabo，Cellular uptake of the tat protein from human immunodeficiencyvirus, Cell, 55 (1988) 1189-1193.
[40]C. Rudolph, C. Plank, J. Lausier, U. Schillinger, R.H. Muller, J. Rosenecker, Oligomers of thearginine-rich motif of the HIV-1 TAT protein are Capable of transferring plasmid DNA intocells, The Journal of biological chemistry, 278 (2003) 11411-11418.
医学硕士论文参考文献三
1.Altenbach, A., J.M. Bemhard, and J. Seckbach, Anoxia: evidence for eukaryote survival andpaleontological strategies. Vol. 21. 2011: Springer.
2.Polge, C.，A.U. Smith, and A.S. Parkes, Revival of Spermatozoa after Vitrification andDehydration at Low Temperatures. Nature, 1949.164(4172): p. 666-666.
3.Smith, A.U., Prevention of Haemolysis during Freezing and Thawing of Red Blood-Cells.Lancet, 1950.259(Dec30): p. 910-911.
4.Lovelock, J.E. and M,W.H. Bishop, Prevention of Freezing Damage to Living Cells byDimethylSulphoxide. Nature, 1959.183(4672): p. 1394-1395.
5.Mazur, R，S.P. Leibo，and E.H.Y. Chu, 2-Factor Hypothesis of Freezing Injury - Evidencefrom Chinese-Hamster Tissue-Culture Cells, Experimental Cell Research, 1972. 71(2); p,345.
6.Fahy, GM., D.R. Macfarlane, C.A. Angell, and H.T. Meryman, Vitrification as an Approachto Cryopreservation. Cryobiology, 1984. 21(4): p. 407-426.
7.Rail, W.F. and G.M. Fahy, Ice-Free Cryopreservation of Mouse Embryos at -19&Degrees-Cby Vitrification. Nature, 1985. 313(6003): p. 573-575.
8.Baust, J.，R. Van Buskirk, and J. Baust, Cryopreservation outcome is enhanced byintracellular'type medium and inhibition of apoptosis. Cryobiology, 1998. 37(4): p. 410-411.
9.Baust, J.M.，R. Van Buskirk, and J.G. Baust, Cell viability improves following inhibition ofcryopreservation-induced apoptosis. In Vitro Cellular & Developmental Biology-Animal,2000. 36(4): p. 262-270.
10.Baust, J.M.，M.J. Vogel，R. Van Buskirk，and J.G. Baust, A molecular basis ofI.cryopreservation failure and its modulation to improve cell survival Cell Transplantation,2001.10(7); p. 561-571.
11.Baust，J.M., R- Van Buskirk, and J.G. Baust, Modulation of the cryopreservation cap:elevated survival with reduced dimethyl sulfoxide concentration. Cryobiology，2002. 45(2); p.97-108.
12.Baust, J.M.，R. Van Buskirk’ and J.G. Baust, Gene activation of the apoptotic caspasecascade following cryogenic storage. Cell Preservation Technology, 2002.1(1): p. 63-80.
13.Gao, D” P. Mazur, and J. Critser, Fundamental cryobiology of mammalian spermatozoa.Reproductive Tissue Banking. Academic Press, New York，1997: p. 263-328.
14.Southard, J.H., T.M. Vangulik, M.S. Ametani, P.K. Vreugdenhil, S.L. Lindell, B.L. Pienaar,and F.O. Belzer, IMPORTANT COMPONENTS OF THE UWSOLUTION. Transplantation,1990. 49(2): p. 251-257.
15.Southard, J.H. and RO. Belzer, ORGAN PRESERVATION. Annual Review of Medicine,1995. 46: p. 235-247.
16.Taylor, M.J.，L.H. Campbell, R.N. Rutledge, and K.G.M. Brockbank, Comparison of Unisolwith Euro-Collins solution as a vehicle solution for cryoprotectants. TransplantationProceedings，2001. 33(1-2): p. 677-679.
17.Lovelock, J.E., THE HAEMOLYSIS OF HUMAN RED BLOOD-CELLS BY FREEZING ANDTHAWING Biochimica Et Biophysica Acta, 1953.10(3); p. 414-426.
18.Van Buskirk, R.G., J.M. Baust, K,K. Snyder, A.J. Mathew, and J.G. Baust, Hypothermicstorage and cryopreservation. Bioprocess International, 2004.
19.Taylor, M.J., Y.C. Song, and K.G. Brockbank, 22 Vitrification in Tissue Preservation: NewDevelopments. 2004.
20.Fahy, G.M., B. Wowk, R. Pagotan, A. Chang, J. Phan, B. Thomson, and L. Phan, Physicaland biological aspects of renal vitrification. Organogenesis, 2009. 5(3): p. 167-175.
21.Baust, J.G. and J.M. Baust, Advances in biopreservation. 2010: CRC Press.
22.Gao, D. and J. Critser, Mechanisms of cryoinjury in living cells. ILAR journal, 2000. 41(4): p.187-196.
23.Mazur, P. and K.W. Cole, INFLUENCE OF CELL CONCENTRATION ON THECONTRIBUTION OF UNFROZEN FRACTION AND SALT CONCENTRATION TO THESURVIVAL OF SLOWLY FROZEN HUMAN-ERYTHROCYTES. Cryobiology, 1985. 22(6): p.509-536.
24.Tani, M. and J.R. Neely, ROLE OF INTRACELLULAR NA+ IN CA-2+ OVERLOAD ANDDEPRESSED RECOVERY OF VENTRICULAR-FUNCTION OF REPERFUSED ISCHEMICRAT HEARTS - POSSIBLE INVOLVEMENT OF H+-NA+ AND NA+-CA2 EXCHANGE.Circulation Research, 1989. 65(4): p. 1045-1056.
25.Renlund, D.G., G. Gerstenblith, E.G. Lakatta, W.E. Jacobus, C.H. Kallman, and ML.Weisfeldt, PERFUSATE SODIUM DURING ISCHEMIA MODIFIES POST-ISCHEMICFUNCTIONAL AND METABOLIC RECOVERY IN THE RABBIT HEART Journal ofMolecular and Cellular Cardiology, 1984. 16(9): p. 795-801.
26.Neely, J.R. and L.W. Grotyohann, ROLE OF GLYCOLYTIC PRODUCTS IN DAMAGE TOISCHEMIC MYOCARDIUM - DISSOCIATION OF ADENOSINE-TRIPHOSPHATELEVELS AND RECOVERY OF FUNCTION OF REPERFUSED ISCHEMIC HEARTS.Circulation Research，1984. 55(6): p. 816-824.
27.Southard, J.H., N.C. Vanderlaan, M. Lutz, GS. Pavlock, J.R Belzer, and F.O. Belzer,COMPARISON OF THE EFFECT OF TEMPERATURE ON KIDNEY CORTEXMITOCHONDRIA FROM RABBIT, DOG, PIG, AND HUMAN - ARRHENIUS PLOTS OFADP-STIMULATED RESPIRATION. Cryobiology, 1983. 20(4): p. 395-400.
28.Nedergaard, J. and B. Cannon，MAMMALIAN HIBERNATION. Philosophical Transactionsof the Royal Society of London Series B-Biological Sciences, 1990. 326(1237): p. 669-686.
29.Brown, R.T. and J.G. Baust, Time course of peripheral heterothermy in a homeotherm. Am JPhysiol，1980. 239: p. R126-R129.
30.Lyons，J.M, and J.K. Raison，TEMPERA WRE-INDUCED TRANSITION INMITOCHONDRIAL OXIDATION - CONTRASTS BETWEEN COLD ANDWARM-BLOODED ANIMALS. Comparative Biochemistry and Physiology, 1970. 37(3): p.405.
31.Raison, J.K., INFLUENCE OF TEMPERATURE-INDUCED PHASE CHANGES ONKINETICS OF RESPIRATORY AND OTHER MEMBRANE-ASSOCIATEDENZYME-SYSTEMS, Journal of Bioenergetics, 1973. 4(1-2): p. 285-309.
32.Ricciutt.Ma, LYSOSOMES AND MYOCARDIAL CELLULAR INJURY. American Journal ofCardiology, 1972. 30(5): p. 498.
33.Weglicki, W.B.，K. Owens, R.C. Ruth, and Sonnenbl.Eh, ACTIVITY OF ENDOGENOUSMYOCARDIAL LIPASES DURING INCUBATION AT ACID PH. Cardiovascular Research,1974. 8(2): p. 237-242.
34.Liu, X., R.M. Engelman, J.A. Rousou, D.K. Das，and D. Das, Myocardial reperfusion injuryduring adult cardiac surgery. 1993: CRC Press，Boca Raton.
35.Dejong，J.W.，CARDIOPLEGIA AND CALCIUM-ANTAGONISTS - A REVIEW. Annals ofThoracic Surgery, 1986. 42(5): p. 593-598.
36.Schwertz, D.W., J. Halverson, T. Isaacson, H. Feinberg, and J.W. Palmer, ALTERATIONS INPHOSPHOLIPID'METABOLISM IN THE GLOBALLY ISCHEMIC RAT-HEART -EMPHASIS ONPHOSPHOINOSITIDE SPECIFIC PHOSPHOLIPASE-C ACTIVITY. Journalof Molecular and Cellular Cardiology, 1987.19(7): p, 685-697.
37.White, B.C., J.G Wiegenstein, and C.D. Winegar, BRAIN ISCHEMIC ANOXIA -MECHANISMS OF INJURY. Jama-Journal of the American Medical Association, 1984.251(12): p. 1586-1590.
38.Jennings, R. and C.E. Ganote, Structural changes in myocardium during acute ischemia.Circulation Rese^ch, 1974. 35: p. 156.
39.Jennings, R.B. and C.E. Ganote, MITOCHONDRIAL STRUCTURE AND FUNCTION INACUTE MYOCARDIAL ISCHEMC-INJURY, Circulation Research, 1976. 38(5): p. 80-91.
40.Clarke, D.M.，J.M. Baust，R.G Van Buskirk, and J.G. Baust, Addition of anticancer agentsenhances freezing-induced prostate cancer cell death: implications of mitochondrialinvolvement. Cryobiology，2004. 49(1): p. 45-61.